Krystal Biotech, Inc. (KRYS) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

18/25

Growth 5 Margin 5 Expansion 3 Platform 1 Financial 4

latest quarter score

Earnings Reports

18
Crystal Biotech (KRYS) Q2 2026: U.S. VYJUVEK Reimbursement Approvals Surpass 730, Driving Deepening Penetration
August 03, 2026
22
Crystal Biotech (KRYS) Q1 2026: Ex-US Revenue Jumps 39% as Global Launch Diversifies Growth
May 04, 2026
22
Crystal Biotech (KRYS) Q4 2025: Ex-US Launches Drive 18% Revenue Growth as Global Expansion Accelerates
February 23, 2026
20
Krystal Biotech (KRYS) Q3 2025: Gross Margin Jumps to 96% as Global Launches Expand
November 03, 2025
21
Crystal Biotech (KRYS) Q2 2025: Vizuvac Revenue Climbs 9% as Global Launches Anchor Multi-Year Growth
August 04, 2025
17
Crystal Biotech (KRYS) Q1 2025: 95% Revenue Growth Anchors Global Vizuvac Expansion
July 07, 2025

Browse all companies